Johnson & JohnsonvsRoyalty Pharma

JNJ and RPRX stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $657B and Royalty Pharma (RPRX) $29.5B. Over the last year, with dividends, JNJ moved +39.7% and RPRX +78.4%. The P/E is 40.8 for JNJ and 43.9 for RPRX. Dividend yield: JNJ 1.94%, RPRX 1.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$657B

    RPRX$29.5B

    JNJ is 22 times RPRX

  • Revenue, 12 months

    JNJ$99.3B

    RPRX$2.6B

    JNJ is 38 times RPRX

  • Net income, 12 months

    JNJ$16.1B

    RPRX$672M

    JNJ is 24 times RPRX

  • Operating margin

    JNJ–

    RPRX57.1%

  • ROIC

    JNJ12.4%

    RPRX6.3%

    6.1 points apart

  • P/E

    JNJ40.8

    RPRX43.9

    RPRX is 1.1 times JNJ

  • Dividend yield

    JNJ1.9%

    RPRX1.4%

    0.5 points apart

  • 5-year return

    JNJ+92.0%

    RPRX+82.2%

    9.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+92.0%

RPRX+82.2%

10015020020222023202420252026
Returns by period
PeriodJNJWith dividendsRPRXWith dividends
1 year since November 17, 2025+39.7%Price +36.6%+78.4%Price +75.4%
3 years since November 17, 2023+98.2%+25.6% a yearPrice +82.1%+177.4%+40.5% a yearPrice +158.2%
5 years since November 17, 2021+92.0%+13.9% a yearPrice +67.0%+82.2%+12.8% a yearPrice +61.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonRPRXRoyalty Pharma

Valuation

JNJRPRX
Valuation
Price$272.70$68.67
Market value$657B$29.5B
Enterprise value (EV)$685B$37.6B
P/E40.843.9
P/E, 5-year median21.917.5
P/B8.13.0
EV/EBIT38.625.1
Free cash flow yield3.1%10.0%

Results and growth

JNJRPRX
Results and growth
Revenue, 12 months$99.3B$2.6B
Net income, 12 months$16.1B$672M
Free cash flow, 12 months$20.6B$3.0B
Earnings per share, 12 months$6.59$1.53
Revenue growth, year on year6.1%5.1%
Revenue growth a year, past+2.7%over 5 years+2.3%over 5 years
EPS growth a year, past+14.9%over 5 years+6.2%over 5 years

Margins and returns on capital

JNJRPRX
Margins and returns on capital
Gross margin67.6%–
Operating margin–57.1%
Net margin16.2%25.7%
ROIC12.4%6.3%
ROE19.7%6.9%

Balance sheet

JNJRPRX
Balance sheet
Cash$17.2B$545M
Total debt$44.7B$8.6B
Net debt / EBITDA1.15.4
Interest cover18.0×4.0×

Dividends and buybacks

JNJRPRX
Dividends and buybacks
Dividend yield1.9%1.4%
Dividend per share, 12 months$5.28$0.94
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%4.2%
Shareholder yield2.9%5.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or RPRX

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Royalty Pharma?

By market value, Johnson & Johnson ($657B) is about 22.3 times Royalty Pharma ($29.5B), at today's prices.

How did JNJ and RPRX stock do over the last 5 years?

Since November 17, 2021, JNJ's price moved +67.0% and RPRX's +61.7%. With dividends: JNJ +92.0% (+13.9% a year), RPRX +82.2% (+12.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or RPRX?

The dividend yield at today's price is 1.94% for Johnson & Johnson and 1.37% for Royalty Pharma. Over the last twelve months they paid $5.28 and $0.94 per share.

What is the P/E of JNJ and RPRX?

At today's price, the P/E is 40.8 for JNJ and 43.9 for RPRX. The median of the last five years was 21.9 and 17.5, which shows where each stands against its own past.

Which has the higher profit margins, Johnson & Johnson or Royalty Pharma?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 25.7% for Royalty Pharma, and the operating margin – and 57.1%. Revenue was $99.3B and $2.6B.

Which is the better investment, Johnson & Johnson or Royalty Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.